Femasys Q2 2026: Sales Fall 18.9%, Net Loss Narrows to $4.47M; $30M Private Placement Closed
FEMY is trading near its 52-week low of $2.19 (6.8% above the low).
Summary
Femasys Q2 2026 sales fell 18.9% to $331,827, net loss narrowed to $4.47M, and a $30M private placement closed August 10, 2026, providing liquidity.
Key Events · Earnings and Guidance · FEMY
-
Q2 Sales Decline
Sales fell 18.9% year-over-year to $331,827, driven by lower international FemVue sales.
-
Net Loss Narrows
Net loss was $4.47M, improved from $4.59M a year ago, helped by non-cash gains on derivative liabilities.
-
$30M Private Placement
Closed August 10, 2026: 9,374,999 shares at $3.20 plus warrants for 18,749,998 shares at $2.95 exercise price.
-
Cash Position
Cash was $1.4M at June 30, 2026; the private placement provides additional liquidity.
Analysis · FEMY · Industrial Applications And Services
Femasys reported Q2 2026 sales of $331,827, down 18.9% year-over-year, while net loss narrowed to $4.47M from $4.59M. The company also disclosed a $30M private placement completed August 10, 2026, with 9,374,999 shares issued at $3.20 and warrants for 18,749,998 shares at $2.95. Cash was $1.4M at quarter-end, but the private placement provides runway. The 10-Q includes full financial statements and MD&A, offering more detail than the earlier 8-K and press release.
At the time of this filing, FEMY was trading at $2.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $2.19 to $22.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.